EntryPoint Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
EntryPoint Capital's VRTX Position: Q1 2026 in Review
EntryPoint Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q1 2026, selling an estimated $253K and leaving 523 shares worth $234K. The position accounts for 0.07% of the portfolio, ranked #580.
EntryPoint Capital first reported a position in VRTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $483K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- EntryPoint Capital held 523 shares of Vertex Pharmaceuticals worth $234K as of Q1 2026.
- EntryPoint Capital sold 543 Vertex Pharmaceuticals shares in Q1 2026, an estimated $253K.
- Vertex Pharmaceuticals made up 0.07% of EntryPoint Capital's portfolio in Q1 2026, its #580 holding.
- EntryPoint Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
- EntryPoint Capital's Vertex Pharmaceuticals position peaked at $483K in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.